Aldosterone and cardiovascular disease

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 3, 2010, Pages 194-198

  Carey, Robert M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Aldosterone; Blood pressure; Clock genes; Fibrosis; Heart; Hypertension; Hypertrophy; Primary aldosteronism; Sodium

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ATORVASTATIN; DEXAMETHASONE; EPLERENONE; GLUCOCORTICOID; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; POTASSIUM CHANNEL; SODIUM; SPIRONOLACTONE; STEROID; TORCETRAPIB; TRILOSTANE;

ALDOSTERONE RELEASE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; CLINICAL RESEARCH; CLINICAL TRIAL; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; MEDICAL LITERATURE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIMARY HYPERALDOSTERONISM; REVIEW; SALT LOADING; TISSUE INJURY;

ALDOSTERONE; ANIMALS; CARDIOVASCULAR DISEASES; CIRCADIAN RHYTHM; DISEASE MODELS, ANIMAL; HUMANS; HYPERALDOSTERONISM; POTASSIUM CHANNELS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, MINERALOCORTICOID;

EID: 77951822096     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283390fa4     Document Type: Review

References (29)

1. Charloux A, Gronfier C, Lonsdorfer-Wolf E, et al. Aldosterone release during the sleep-wake cycle in humans. Am J Physiol 1999; 276:E43-E49. (Pubitemid 29065592)
2. Peixoto AJ, White WB. Circadian blood pressure: clinical implications based on the pathophysiology of its variability. Kidney Int 2007; 71:855-860.
3. Doi M, Takahashi Y, Komatsu R, et al. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med 2010; 16:67-74.
4. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:3266-3281.
5. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:510-526.
6. Davies LA, Hu C, Guagliardo NA, et al. TASK channel deletion in mice causes primary hyperaldosteronism. ProcNatl Acad Sci. USA 2008; 105:2203-2208. (Pubitemid 351439489)
7. Grimm PR, Irsik DL, Settles DC, et al. Hypertension of Kcnmb-/- is linked to deficient K secretion and aldosteronism. Proc Nat Acad Sci U S A 2009; 106:11800-11805.
8. Rieg T, Vallon V, Sausbier M, et al. The role of the BK channel in potassium homeostasis and flow-induced renal potassium excretion. Kidney Int 2007; 72:566-573. (Pubitemid 47312793)
9. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168:1159-1164.
10. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 53:475-481.
11. deSouza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55:147-152.
12. Pitt B, Zannad F, Remme W, et al., for the Randomized Aldactone Evaluation Study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717.
13. Pitt B, Remme S, Kleiman J, Gatlin M, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
14. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009; 53 (part 2):286-290.
15. Sato A, Funder JW. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinol 1996; 137:4145-4153. (Pubitemid 26321859)
16. Mihailidou AS, Le TYL, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009; 54:1306-1312.
17. Kotchen TA. Editorial commentary: sodium chloride and aldosterone: harbingers of hypertension-related cardiovascular disease. Hypertension 2009; 54:449-450.
18. Jin Y, Kuznetsova T, Maillard M, et al. Independent relations of left ventribular structure with the 24-h urinary excretion of sodium and aldosterone. Hypertension 2009; 54:489-495.
19. Lemarie CA, Paradis P, Schiffrin EL. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med 2008; 86:673-678.
20. Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensininduced vascular changes and oxidative stress. Hypertension 2002; 40:504-510.
21. Harada E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensinconverting enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001; 104:137-139. (Pubitemid 32655827)
22. Schiffrin EL, Gutowska J, Genest J. Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am J Physiol 1984; 246:H608-H614. (Pubitemid 14148855)
23. Johar S, Cave AC, Narayanapanicker A, et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 2006; 20:1546-1548. (Pubitemid 44943825)
24. Zhang AD, Cat AND, Soukaseum C, et al. Cross-talk between mineralocorticoid and angiotensin signaling for cardiac remodeling. Hypertension 2008; 52:1060-1067.
25. Funder JW. Aldosterone, sodium, and hypertension: lessons from torcetrapib? Hypertension 2009; 55:221-223.
26. Hasegawa T, Masugi F, Ogihara T, Kumahara Y. Increase in plasma ouabainlike inhibitor of Na+, K+-ATPase with high sodium intake in patients with essential hypertension. J Clin Hypertens 1987; 3:419-429.
27. Li Z, Xie Z. The Na/K-ATPase/Src complex and cardiotonic steroid-activated protein kinase cascades. Pflugers Arch 2009; 457:635-644.
28. Zhang J, Lee MY, Cavalli M, et al. Sodium pump a2 subunits control myogenic tone and blood pressure in mice. J Physiol 2005; 569:245-256. (Pubitemid 41701389)
29. Tian J, Shidyak A, Peryasamy SM, et al. Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. Hypertension 2009; 54:1313-1320.